Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 2
2011 1
2014 2
2015 2
2018 2
2023 3
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis.
Tarvin SE, Sherman MA, Kim H, Balmuri N, Brown AG, Chow A, Gewanter HL, de Guzman MM, Huber AM, Kim S, Klein-Gitelman MS, Perron MM, Robinson AB, Sabbagh SE, Savani S, Shenoi S, Spitznagle J, Stingl C, Syverson G, Tory H, Spencer C; Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup. Tarvin SE, et al. Arthritis Care Res (Hoboken). 2024 Nov;76(11):1532-1539. doi: 10.1002/acr.25393. Epub 2024 Aug 14. Arthritis Care Res (Hoboken). 2024. PMID: 38937134
Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.
Sherman MA, Kim H, Banschbach K, Brown A, Gewanter HL, Lang B, Perron M, Robinson AB, Spitznagle J, Stingl C, Syverson G, Tory HO, Spencer CH, Tarvin SE. Sherman MA, et al. Among authors: tarvin se. Pediatr Rheumatol Online J. 2023 Jan 6;21(1):3. doi: 10.1186/s12969-022-00785-5. Pediatr Rheumatol Online J. 2023. PMID: 36609397 Free PMC article.
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.
Ogbu EA, Brunner HI, Eloseily E, Aviel YB, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Wahezi DM, Tarvin SE, Sproles A, Chen C, Ruperto N, Huang B, Grom A, Thornton S; Investigators of the PRINTO and PRCSG Networks. Ogbu EA, et al. Among authors: tarvin se. Arthritis Care Res (Hoboken). 2024 Dec;76(12):1723-1732. doi: 10.1002/acr.25417. Epub 2024 Sep 17. Arthritis Care Res (Hoboken). 2024. PMID: 39135452 Free PMC article.
Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2023 Sep;75(9):1668-1677. doi: 10.1002/art.42512. Epub 2023 Jul 19. Arthritis Rheumatol. 2023. PMID: 36996276 Free PMC article.
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.
Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, Verbsky JW, Spalding SJ, Kimura Y, Imundo LF, Punaro MG, Sherry DD, Tarvin SE, Zemel LS, Birmingham JD, Gottlieb BS, Miller ML, O'Neil K, Ruth NM, Wallace CA, Singer NG, Sandborg CI. Ilowite NT, et al. Among authors: tarvin se. Arthritis Rheumatol. 2014 Sep;66(9):2570-9. doi: 10.1002/art.38699. Arthritis Rheumatol. 2014. PMID: 24839206 Free PMC article. Clinical Trial.
15 results